CANbridge doses first patient in phase 2 EMBARK study of CAN108 in BA

CANbridge Pharmaceuticals has dosed the first patient in the phase 2 EMBARK study of CAN108 (maralixibat) in biliary atresia (BA) in China. The clinical trial ... Read More